MedPath

High Flow Nasal Cannula on Exercise Endurance in COPD

Not Applicable
Completed
Conditions
COPD
Interventions
Device: high flow nasal cannula
Device: nasal cannula
Registration Number
NCT03883256
Lead Sponsor
Chang Gung University
Brief Summary

Ventilation limitation has a significant adverse effects on cardiovascular function and cerebral oxygenation during exercise in patients with COPD. High flow nasal cannula (HFNC) has been shown to improve ventilation by washing out the anatomical dead space and permitting a better gas exchanges. Moreover, it is able to ensure the desired inspired oxygen fraction (FiO2) even at high level of patient's minute ventilation by minimizing the room air entrainment. The effects of HFNC on exercise performance in terms of hemodynamic changes and exercise endurance in COPD patients remain unclear. The primary purpose of this study is to examine the effects of HFNC on the exercise endurance in COPD patients. The investigator's secondary purpose is to investigate whether HFNC could improve efficiency of ventilation, leading to an improvement of hemodynamic and cerebral oxygenation response.

Detailed Description

This is a randomized crossover study. Patients who have been diagnosed as COPD will be recruited from outpatient department. After signing informed consent form, patients undertake an incremental exercise test and two constant load exercise at the 70% of maximum workload achieved at a previous incremental exercise test on arm ergometer in two separate days. The constant load tests will be performed with HFNC and with nasal cannula at the same inhaled oxygen fraction in random order. The hemodynamics CO, SV, EF of all subjects during exercises will be measured by a bioelectrical impedance device (Physioflow), and cerebral oxygenation status (oxygenated hemoglobin (O2Hb), deoxygenated hemoglobin (HHb), total hemoglobin (tHb) was measured by a near infrared spectrophotometer (NIRS).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
15
Inclusion Criteria
  1. with diagnosis of COPD
  2. OPD patients
  3. has no AE (within 1 month)
  4. not receiving any O2 therapy at home
  5. no smoking or quick
Exclusion Criteria
  1. fever
  2. unstable hemodynamics at resting
  3. orthopadeic or neurologic problems that limited exercise

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
high flow nasal cannulahigh flow nasal cannulaSubjects perform a constant-load exercise test with high flow nasal cannula oxygen device.
nasal cannulanasal cannulaSubjects perform a constant-load exercise test with nasal cannula oxygen device.
Primary Outcome Measures
NameTimeMethod
exercise time with high flow nasal cannulaend of the exercise test in the session of constant-load exercise test with high flow nasal cannula oxygen device

the total duration that subjects performed constant-load exercise test with high flow nasal cannula oxygen device

exercise time with nasal cannulaend of the exercise test in the session of constant-load exercise test with nasal cannula oxygen device

the total duration that subjects performed constant-load exercise test with nasal cannula oxygen device

Secondary Outcome Measures
NameTimeMethod
Difference in muscle tissue oxygenationBaseline and 48 hours after baseline ]

Difference in end-exercise muscle tissue oxygenation in constant-load exercise test between HFNCO and NC

Difference in cardiac outputBaseline and 48 hours after baseline ]

Difference in end-exercise cardiac output in constant-load exercise test between HFNCO and NC

Difference in stroke volumeBaseline and 48 hours after baseline ]

Difference in end-exercise stroke volume in constant-load exercise test between HFNCO and NC

Difference in cerebral tissue oxygenationBaseline and 48 hours after baseline ]

Difference in end-exercise cerebral tissue oxygenation in constant-load exercise test between HFNCO and NC

Trial Locations

Locations (1)

Chang Gung University

🇨🇳

TaoYuan City, Taiwan

© Copyright 2025. All Rights Reserved by MedPath